Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis
Open Access
- 1 September 2015
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (3) , 410-419.e6
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasisJournal of the American Academy of Dermatology, 2013
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseAnnals of the Rheumatic Diseases, 2013
- Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysisAnnals of the Rheumatic Diseases, 2011
- The Long-Term Safety of Adalimumab Treatment in Moderate to Severe PsoriasisAmerican Journal of Clinical Dermatology, 2011
- Long-term prognosis in patients with psoriasisBritish Journal of Dermatology, 2008
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningJournal of the American Academy of Dermatology, 2008
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- TNF- α inhibitorsDermatologic Therapy, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumabJournal of Dermatological Treatment, 2004